Brookline Capital Management Estimates HURA Q2 Earnings

TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) - Brookline Capital Management issued their Q2 2025 earnings per share (EPS) estimates for shares of TuHURA Biosciences in a report released on Monday, June 23rd. Brookline Capital Management analyst K. Raja anticipates that the company will post earnings of ($0.15) per share for the quarter. Brookline Capital Management has a "Strong-Buy" rating on the stock. Brookline Capital Management also issued estimates for TuHURA Biosciences' Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.60) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.43) EPS and FY2029 earnings at $0.08 EPS.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02).

Several other equities research analysts have also recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of TuHURA Biosciences in a report on Friday, May 16th. Wall Street Zen cut TuHURA Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. One analyst has rated the stock with a sell rating, three have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $12.67.

TuHURA Biosciences Price Performance

HURA traded down $0.07 during trading hours on Wednesday, reaching $2.22. 2,950,027 shares of the company's stock traded hands, compared to its average volume of 259,785. The firm has a 50-day moving average price of $3.27 and a 200 day moving average price of $3.66. TuHURA Biosciences has a 52-week low of $1.80 and a 52-week high of $7.93.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in HURA. Charles Schwab Investment Management Inc. bought a new position in shares of TuHURA Biosciences in the 4th quarter worth $61,000. Accent Capital Management LLC bought a new position in shares of TuHURA Biosciences in the 4th quarter worth $29,000. Geode Capital Management LLC bought a new position in shares of TuHURA Biosciences in the 4th quarter worth $1,084,000. Hurlow Wealth Management Group Inc. bought a new position in shares of TuHURA Biosciences in the 4th quarter worth $170,000. Finally, TT Capital Management LLC bought a new position in shares of TuHURA Biosciences in the 4th quarter worth $41,000. 0.62% of the stock is owned by institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.